• Ticker

DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$62.25 -$0.17 (-0.27%)

REAL-TIME: Last trade at

Abbott Laboratories

NYSE:ABT

3 Reasons To Buy Johnson & Johnson

Insurance For Health Care Stocks

Abbott Wants To Extract More From Humira While Pfizer Slogs Along With Lipitor

Emergent, Pfizer, Abbott Looking Strong In Their Fields

Biotechnology Stocks To Watch Ahead Of ASCO 2012: Part 2

'Buy Zones' For The DIY Dividend Portfolio Part 3b: Healthcare

Gen-Probe Remains Neutral - Analyst Blog

Orbimed's $3.4B Filing: 2 Stocks It And Other Healthcare Funds Bought In Q1, And Other Trades

Johnson & Johnson: An Uncommon Opportunity

Gilead Drug Up for European Review - Analyst Blog

Abbott Aims Pediatric Nutritional Market With New Beverage

Why Abbott Is A Buy After The Lawsuit

Zacks' Voice of the People highlights opportunities with Johnson & Johnson, Disney, Abbott Labs and

Pharma Updates: Pfizer Recalls Advil & Merck’s Propecia Causes Furor

JNJ Updates: Positives For Xarelto & Simponi

Abbott Bid For US Approval Of New Use For Humira Is Delayed

Abbott Updates: Niaspan Losing Vigor, But Nutritionals Going Strong

Auxilium-Glaxo to Drive Testim Sales - Analyst Blog

1 Great Dividend to Buy Today

RobMarketsBlind's Latest Purchase - Voice of the People

J&J's Simponi Helps Colitis Patients In Clinical Trial

1 Great Dividend You Can Buy Right Now

5 Pharmaceutical Stocks With Significant Exposure to Europe

Myriad to Present Cancer Test Study - Analyst Blog

Pfizer’s Pipeline: Drugs To Watch Post Lipitor

2 Reasons That Cystic Fibrosis Trumps Hep C

Abbott Stands Up to Obamacare

Johnson & Johnson’s CEO Looks To Bolster Cardiology Devices Segment Through Acquisitions

The Zacks Analyst Blog Highlights: Gilead Sciences, Abbott Labs, Alliance Data Systems Corporation,

Panel Votes in Favor of Pfizer Drug - Analyst Blog

Johnson & Johnson’s CEO Looks To Bolster Cardiology Devices Segment Through Acquisitions

HIV Drug Maker Gilead Sciences Scores Two Wins

Zacks Bull and Bear of the Day Highlights: Eastman Chemical, Kirkland's, Biogen Idec, Abbott, Novart

A Step Closer to Quadrific Sales

Good News for Gilead - Analyst Blog

FDA Approves Gen-Probe's PANTHER - Analyst Blog

Diet Pill Maker Arena Pharmaceuticals Wins Backing of FDA Advisers

Abbott Settles Depakote Suit For $1.5 billion; Urges FDA To Block Generics

Standard Review for Biogen's BG-12 - Analyst Blog

Abbott Settles Depakote Suit For $1.5 billion; Urges FDA To Block Generics

See More Articles...